IL150227A0 - Processes for preparing clarithromycin polymorphs and novel polymorph iv - Google Patents

Processes for preparing clarithromycin polymorphs and novel polymorph iv

Info

Publication number
IL150227A0
IL150227A0 IL15022700A IL15022700A IL150227A0 IL 150227 A0 IL150227 A0 IL 150227A0 IL 15022700 A IL15022700 A IL 15022700A IL 15022700 A IL15022700 A IL 15022700A IL 150227 A0 IL150227 A0 IL 150227A0
Authority
IL
Israel
Prior art keywords
clarithromycin
processes
novel polymorph
present
converting
Prior art date
Application number
IL15022700A
Other languages
English (en)
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of IL150227A0 publication Critical patent/IL150227A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08Hetero rings containing eight or more ring members, e.g. erythromycins

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Polyamides (AREA)
  • Medicinal Preparation (AREA)
IL15022700A 1999-12-16 2000-12-15 Processes for preparing clarithromycin polymorphs and novel polymorph iv IL150227A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17122199P 1999-12-16 1999-12-16
US17183999P 1999-12-22 1999-12-22
PCT/US2000/033845 WO2001044262A1 (en) 1999-12-16 2000-12-15 Processes for preparing clarithromycin polymorphs and novel polymorph iv

Publications (1)

Publication Number Publication Date
IL150227A0 true IL150227A0 (en) 2002-12-01

Family

ID=26866853

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15022700A IL150227A0 (en) 1999-12-16 2000-12-15 Processes for preparing clarithromycin polymorphs and novel polymorph iv

Country Status (20)

Country Link
US (2) US6599884B2 (cs)
EP (1) EP1254146B1 (cs)
JP (1) JP2003516999A (cs)
KR (1) KR20020070991A (cs)
CN (2) CN1217951C (cs)
AT (1) ATE302786T1 (cs)
AU (1) AU783055B2 (cs)
CA (1) CA2395555A1 (cs)
CZ (1) CZ20021999A3 (cs)
DE (1) DE60022230T2 (cs)
ES (1) ES2244491T3 (cs)
HR (1) HRP20020522A2 (cs)
HU (1) HUP0204091A3 (cs)
IL (1) IL150227A0 (cs)
PL (1) PL364880A1 (cs)
PT (1) PT1254146E (cs)
RU (1) RU2002116232A (cs)
SK (1) SK8322002A3 (cs)
WO (1) WO2001044262A1 (cs)
YU (1) YU45602A (cs)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0016992A (pt) * 2000-01-11 2002-12-31 Teva Pharma Processos para o preparo de polimorfos de claritromicina
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6565882B2 (en) 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
EP1313486A1 (en) * 2000-02-29 2003-05-28 Teva Pharmaceutical Industries Ltd. Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same
NZ521368A (en) * 2000-03-28 2004-05-28 Biochemie Ges M Granulated particles of an active compound, with a film-forming coating resulting in the masked taste of said active compound
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US6541014B2 (en) 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
CA2533178C (en) 2003-07-21 2014-03-11 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
WO2005009368A2 (en) 2003-07-21 2005-02-03 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
AU2004258944B2 (en) 2003-07-21 2011-02-10 Shionogi, Inc. Antibiotic product, use and formulation thereof
AU2004264939A1 (en) 2003-08-11 2005-02-24 Middlebrook Pharmaceuticals, Inc. Robust pellet
EP1653924A4 (en) 2003-08-12 2009-09-09 Middlebrook Pharmaceuticals In ANTIBIOTICS, USE AND FORMULATION ASSOCIATED
US8246996B2 (en) 2003-08-29 2012-08-21 Shionogi Inc. Antibiotic product, use and formulation thereof
WO2005027877A1 (en) 2003-09-15 2005-03-31 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
WO2005061524A2 (en) * 2003-12-22 2005-07-07 Ranbaxy Laboratories Limited Process for the preparation of form ii clarithromycin
CA2550983C (en) * 2003-12-24 2013-09-17 Advancis Pharmaceutical Corporation Enhanced absorption of modified release dosage forms
JP2008505124A (ja) 2004-07-02 2008-02-21 アドバンシス ファーマスーティカル コーポレイション パルス送達用錠剤
CA2614412A1 (en) * 2005-07-07 2007-01-18 Elan Pharma International, Limited Nanoparticulate clarithromycin formulations
WO2007036951A2 (en) * 2005-08-31 2007-04-05 Alembic Limited Process to obtain 6-o-methylerythromycin a (clarithromycin)_form ii
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
DE102007016367A1 (de) 2007-04-03 2008-10-09 Grünenthal GmbH Polymorph von Clarithromycin (Form V)
EP2030613A1 (en) 2007-08-17 2009-03-04 Abbott GmbH & Co. KG Preparation of compositions with essentially noncrystalline embedded macrolide antibiotics
US9119769B2 (en) 2011-12-30 2015-09-01 The Curators Of The University Of Missouri Method for transforming pharmaceutical crystal forms
CN103087130B (zh) * 2013-02-06 2015-12-23 浙江国邦药业有限公司 一种克拉霉素晶型转换方法
KR102381295B1 (ko) 2013-11-15 2022-03-31 아케비아 테라퓨틱스 인코포레이티드 {[5-(3-클로로페닐)-3-하이드록시피리딘-2-카보닐]아미노}아세트산의 고체형, 이의 조성물 및 용도

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4954572A (cs) * 1972-09-29 1974-05-27
FR2473525A1 (fr) 1980-01-11 1981-07-17 Roussel Uclaf Nouvelles oximes derivees de l'erythromycine, leur procede de preparation et leur application comme medicaments
US4331803A (en) 1980-06-04 1982-05-25 Taisho Pharmaceutical Co., Ltd. Novel erythromycin compounds
JPS60214796A (ja) 1984-04-06 1985-10-28 Taisho Pharmaceut Co Ltd 6−0−メチルエリスロマイシン類の製法
JPS61103890A (ja) 1984-10-26 1986-05-22 Taisho Pharmaceut Co Ltd 6−0−メチルエリスロマイシンa誘導体
US4670549A (en) 1985-03-18 1987-06-02 Taisho Pharmaceutical Co., Ltd. Method for selective methylation of erythromycin a derivatives
US4660386A (en) * 1985-09-18 1987-04-28 Hansen John C Diagnostic system for detecting faulty sensors in liquid chiller air conditioning system
US4640910A (en) 1985-11-12 1987-02-03 Abbott Laboratories Erythromycin A silylated compounds and method of use
US4672056A (en) 1985-11-12 1987-06-09 Abbott Laboratories Erythromycin A derivatives and method of use
KR960000434B1 (ko) 1986-12-17 1996-01-06 다이쇼 세이야꾸 가부시끼가이샤 에리스로마이신 a유도체 및 그의 제조 방법
GB8721165D0 (en) 1987-09-09 1987-10-14 Beecham Group Plc Chemical compounds
JP2751385B2 (ja) 1988-05-19 1998-05-18 大正製薬株式会社 エリスロマイシンaオキシム及びその塩の製造方法
US5274065A (en) * 1990-10-18 1993-12-28 Technical Development Associates Polyorganosiloxane-polyamide block copolymers
JPH0665080A (ja) * 1992-03-10 1994-03-08 Godo Shiyusei Kk α−グルコシダ−ゼ阻害剤を含有する、過血糖付随疾患の予防・治療剤、および保健食
US5872229A (en) 1995-11-21 1999-02-16 Abbott Laboratories Process for 6-O-alkylation of erythromycin derivatives
US5756473A (en) 1995-11-21 1998-05-26 Abbott Laboratories 6-O-methyl erythromycin D and process for making
US5719272A (en) 1996-04-02 1998-02-17 Abbott Laboratories 2'-protected 3'-dimethylamine, 9-etheroxime erythromycin A derivatives
US5837829A (en) 1996-04-02 1998-11-17 Abbott Laboratories 9-oximesilyl erythromycin a derivatives
US5808017A (en) 1996-04-10 1998-09-15 Abbott Laboratories Process for preparing erythromycin A oxime
US5844105A (en) * 1996-07-29 1998-12-01 Abbott Laboratories Preparation of crystal form II of clarithromycin
US5858986A (en) 1996-07-29 1999-01-12 Abbott Laboratories Crystal form I of clarithromycin
DE97934319T1 (de) 1996-07-29 2004-08-26 Abbott Laboratories, Abbott Park Herstellung von kristallinen form ii von clarithromycin
US5945405A (en) 1997-01-17 1999-08-31 Abbott Laboratories Crystal form O of clarithromycin
US5864023A (en) 1997-02-13 1999-01-26 Abbott Laboratories 3'-N'oxide, 3'-n-dimethylamine, 9-oxime erythromycin a derivatives
US5852180A (en) 1997-11-17 1998-12-22 Abbott Laboratories Chemical synthesis of 6-O-alkyl erythromycin A
US5932710A (en) 1997-12-01 1999-08-03 Abbott Laboratories Process for preparing 6-O-alkyl-9-oxime erythromycin B
US5892008A (en) 1997-12-16 1999-04-06 Abbott Laboratories Process for the preparation of 6-O-methyl erythromycin a using 9-hydroxy erythromycin derivatives
KR100377159B1 (ko) 1998-09-09 2003-08-19 한미약품공업 주식회사 잔류 용매가 없는 클라리스로마이신의 결정형 2의 제조 방법
WO2000077017A1 (en) * 1999-06-11 2000-12-21 Ranbaxy Laboratories Limited Novel amorphous form of clarithromycin
BR0016992A (pt) * 2000-01-11 2002-12-31 Teva Pharma Processos para o preparo de polimorfos de claritromicina
EP1313486A1 (en) * 2000-02-29 2003-05-28 Teva Pharmaceutical Industries Ltd. Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same

Also Published As

Publication number Publication date
AU2431101A (en) 2001-06-25
SK8322002A3 (en) 2003-02-04
HUP0204091A2 (hu) 2003-04-28
EP1254146A1 (en) 2002-11-06
ATE302786T1 (de) 2005-09-15
CN1434829A (zh) 2003-08-06
AU783055B2 (en) 2005-09-22
DE60022230T2 (de) 2006-01-26
US6599884B2 (en) 2003-07-29
WO2001044262A1 (en) 2001-06-21
KR20020070991A (ko) 2002-09-11
HUP0204091A3 (en) 2003-05-28
CA2395555A1 (en) 2001-06-21
JP2003516999A (ja) 2003-05-20
US20020026038A1 (en) 2002-02-28
CZ20021999A3 (cs) 2003-02-12
RU2002116232A (ru) 2004-01-10
YU45602A (sh) 2005-06-10
PT1254146E (pt) 2005-10-31
US20040058879A1 (en) 2004-03-25
EP1254146B1 (en) 2005-08-24
CN1217951C (zh) 2005-09-07
DE60022230D1 (de) 2005-09-29
CN1666991A (zh) 2005-09-14
ES2244491T3 (es) 2005-12-16
EP1254146A4 (en) 2003-04-16
PL364880A1 (en) 2004-12-27
HRP20020522A2 (en) 2004-12-31

Similar Documents

Publication Publication Date Title
IL150227A0 (en) Processes for preparing clarithromycin polymorphs and novel polymorph iv
NZ534374A (en) Method of synthesizing camptothecin-relating compounds
AP1709A (en) Ethanolate of azithromycin, process for manufacure, and pharmaceutical compositions thereof.
BG103673A (en) 3'-n-oxide, 3'-n-dimethylamine, 9-oxime derivatives of erythromycin a
HUP0200076A3 (en) C-21 modified epothilones, process for their preparation, pharmaceutical compositions containing them
PL364598A1 (en) Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments
PL392726A1 (pl) Nowe związki pośrednie do syntezy związków triazolopirymidyny oraz sposób ich wytwarzania
IL140419A0 (en) Novel form of irbesartan, methods for obtaining said form and pharmaceutical compositions containing same
HUP0202186A3 (en) Benzimidazolone derivatives, process for their preparation, pharmaceutical compositions containing them and their use as phosphodiesterase inhibitors for producing pharmaceutical compositions
AP9801378A0 (en) 9-amino-3- keto erythromycin derivatives.
CA2468649A1 (en) Adenosine a2a receptor antagonists
CA2280310A1 (en) Nmda antagonist
HUP0200580A3 (en) Polymorphic crystalline forms of celecoxib, process their preparation and pharmaceutical compositions containing them
EP0992509A3 (en) Novel macrolide derivatives
CA2412047A1 (en) Shortened synthesis of 3,3-diarylpropylamine derivatives
BG105197A (en) Polymorph form of a medicament
WO2002042315A3 (en) Macrolide solvates
CA2462998A1 (en) Novel estrogenic compounds
HUP0201710A3 (en) Biphenyl derivatives as antagonists of the neurokinine-1 receptor, process for producing them and pharmaceutical compositions containing them
UA66866C2 (uk) Синтез морфолінових похідних
HUP0102631A3 (en) 1,1- and 1,2-disubstituted cyclopropane derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0105116A3 (en) 2,3-0-isopropylidene derivatives of monosaccharides as cell adhesion inhibitors, pharmaceutical compositions containing them, process for preparation of the compounds
GB0105335D0 (en) C2,8-disubstituted adenosine derivatives and their different uses
BG106002A (en) Process for preparing pesticidal intermediates
AP9801235A0 (en) Erythromycin derivatives.